ClinicalTrials.Veeva

Menu

Validation of a Virtual Reality Test for the Assessment of Visually Impaired Patients Undergoing Low Vision Rehabilitation (VisionumVR)

F

Fondation Ophtalmologique Adolphe de Rothschild

Status

Enrolling

Conditions

Low Vision

Treatments

Device: test visionumVR

Study type

Interventional

Funder types

NETWORK
Industry

Identifiers

NCT07092124
P_VST_2025_2

Details and patient eligibility

About

Low vision rehabilitation is a vital part of care for visually impaired patients, who are usually referred to orthoptists to develop visual strategies and optimize residual vision. This rehabilitation significantly improves quality of life by enhancing autonomy and reducing depression. It employs various tools, from traditional exercises to specialized software. Advances in virtual reality (VR) offer new promising opportunities by creating immersive environments tailored to patients' residual vision, increasing motivation and exercise effectiveness. In this context, VisionumVR was developed-a VR test using the Meta Quest 3 headset to assess functional vision during rehabilitation. It evaluates hand-eye coordination, visual discrimination, and visual exploration through a daily-life-inspired task. This standardized 20-minute test aims to measure patients' progress throughout their orthoptic rehabilitation.

Enrollment

60 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient (regardless of visual pathology) who is about to begin or has begun orthoptic low vision rehabilitation;
  • Patient requiring at least five orthoptic rehabilitation sessions that can be completed before the end of the study;
  • Binocular visual acuity ≥ 1/20 (≤ 1.3 logMAR), regardless of type of vision loss (central, mixed, or peripheral);
  • Sufficient knowledge of the French language.

Exclusion criteria

  • Neurodegenerative diseases or any other condition that could interfere with the planned assessments in this study (known epilepsy and/or history of seizures, dysfunction of the dominant upper limb, etc.);
  • Medications that may cause motor, visual, or cognitive impairments (neuroleptics, etc.) or interfere with the study assessments;
  • Pregnant women (pregnancy can cause vision fluctuations, and wearing a virtual reality headset is not recommended);
  • Participation in another clinical trial that may interfere with the current study;
  • Inability to follow instructions or read.

Trial design

Primary purpose

Other

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

60 participants in 1 patient group

Test visionumVR
Experimental group
Treatment:
Device: test visionumVR

Trial contacts and locations

2

Loading...

Central trial contact

Amelie Yavchitz, Dr

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems